19.02.2024 15:29:23

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 19 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023.

Under the programme initiated 6 February 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.1 billion in the period from 6 February 2024 to 30 April 2024.

Since the announcement 12 February 2024, the following transactions have been made:

  Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 179,000   146,605,323
12 February 2024 43,000 834.96 35,903,384
13 February 2024 43,000 833.76 35,851,692
14 February 2024 44,000 838.42 36,890,697
15 February 2024 43,000 847.54 36,444,198
16 February 2024 42,500 846.54 35,977,766
Accumulated under the programme 394,500   327,673,060

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 46,935,207 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is 4,510,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 16 February 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 394,500 B shares at an average share price of DKK 830.60 per B share equal to a transaction value of DKK 327,673,060.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contact for further information

Media:  
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

 
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com

 
Investors:  
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com

 
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

 
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

 
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

 
Sina Meyer
+45 3079 6656
azey@novonordisk.com

 
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com

 

CA 16 


Attachments


Analysen zu Novo Nordiskmehr Analysen

27.11.24 Novo Nordisk Buy Deutsche Bank AG
27.11.24 Novo Nordisk Buy Goldman Sachs Group Inc.
18.11.24 Novo Nordisk Neutral UBS AG
15.11.24 Novo Nordisk Buy Goldman Sachs Group Inc.
13.11.24 Novo Nordisk Neutral UBS AG
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Novo Nordisk 100,42 -0,02% Novo Nordisk